TrialPLoS pathogens2021

PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection.

Sean C Murphy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.